<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ketamineone Capital Limited — News on 6ix</title>
    <link>https://6ix.com/company/ketamineone-capital-limited</link>
    <description>Latest news and press releases for Ketamineone Capital Limited on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 16 Feb 2023 22:32:36 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ketamineone-capital-limited" rel="self" type="application/rss+xml" />
    <item>
      <title>Wellbeing Provides Bi-Weekly Default Status Report</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-provides-bi-weekly-default-status-report</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-provides-bi-weekly-default-status-report</guid>
      <pubDate>Thu, 16 Feb 2023 22:32:36 GMT</pubDate>
      <description>Wellbeing Provides Bi-Weekly Default Status Report.</description>
    </item>
    <item>
      <title>Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-announces-publication-of-safety-studies-on-paraxanthine-and-comparison-to-caffeine-toxicity</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-announces-publication-of-safety-studies-on-paraxanthine-and-comparison-to-caffeine-toxicity</guid>
      <pubDate>Wed, 15 Feb 2023 13:33:51 GMT</pubDate>
      <description>Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity..</description>
    </item>
    <item>
      <title>Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-receives-exemption-under-section-56-of-the-controlled-drugs-and-substances-act-to-begin-psilocybin-clinical-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-receives-exemption-under-section-56-of-the-controlled-drugs-and-substances-act-to-begin-psilocybin-clinical-trial</guid>
      <pubDate>Tue, 14 Feb 2023 13:32:55 GMT</pubDate>
      <description>Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial.</description>
    </item>
    <item>
      <title>Wellbeing Digital Announces Change of Auditor</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-announces-change-of-auditor</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-announces-change-of-auditor</guid>
      <pubDate>Wed, 18 Jan 2023 21:21:38 GMT</pubDate>
      <description>Wellbeing Digital Announces Change of Auditor.</description>
    </item>
    <item>
      <title>Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-receives-approval-for-first-of-its-kind-psylocibin-clinical-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-receives-approval-for-first-of-its-kind-psylocibin-clinical-trial</guid>
      <pubDate>Thu, 22 Dec 2022 21:15:39 GMT</pubDate>
      <description>Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial.</description>
    </item>
    <item>
      <title>Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-awarded-cannabis-research-license-from-health-canada</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-awarded-cannabis-research-license-from-health-canada</guid>
      <pubDate>Thu, 08 Dec 2022 13:10:39 GMT</pubDate>
      <description>Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada.</description>
    </item>
    <item>
      <title>Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-announces-successful-results-of-up446-a-nutraceutical-ingredient-in-positive-immune-defense-response</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-announces-successful-results-of-up446-a-nutraceutical-ingredient-in-positive-immune-defense-response</guid>
      <pubDate>Tue, 06 Dec 2022 12:31:07 GMT</pubDate>
      <description>Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response.</description>
    </item>
    <item>
      <title>Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-submits-cta-for-phase-iia-clinical-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-submits-cta-for-phase-iia-clinical-trial</guid>
      <pubDate>Wed, 30 Nov 2022 13:30:40 GMT</pubDate>
      <description>Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial.</description>
    </item>
    <item>
      <title>Wellbeing Subsidiary Mindscape Treats its 1,000th Patient</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-mindscape-treats-its-1000th-patient</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-mindscape-treats-its-1000th-patient</guid>
      <pubDate>Tue, 29 Nov 2022 12:32:43 GMT</pubDate>
      <description>Wellbeing Subsidiary Mindscape Treats its 1,000th Patient.</description>
    </item>
    <item>
      <title>Wellbeing Digital Announces the Appointment of Mohammad Sharifi to Board of Directors</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-announces-the-appointment-of-mohammad-sharifi-to-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-announces-the-appointment-of-mohammad-sharifi-to-board-of-directors</guid>
      <pubDate>Tue, 22 Nov 2022 22:18:09 GMT</pubDate>
      <description>Wellbeing Digital Announces the Appointment of Mohammad Sharifi to Board of Directors.</description>
    </item>
    <item>
      <title>Wellbeing Digital Announces Resignation of Directors</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-announces-resignation-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-announces-resignation-of-directors</guid>
      <pubDate>Fri, 18 Nov 2022 21:30:20 GMT</pubDate>
      <description>Wellbeing Digital Announces Resignation of Directors.</description>
    </item>
    <item>
      <title>Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-enters-into-research-contract-with-nova-mentis-for-phase-ii-a-clinical-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-enters-into-research-contract-with-nova-mentis-for-phase-ii-a-clinical-trial</guid>
      <pubDate>Thu, 17 Nov 2022 13:30:38 GMT</pubDate>
      <description>Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial.</description>
    </item>
    <item>
      <title>Wellbeing Subsidiary KGK Science Announces Successful Delivery of CBD and THC Through the Skin of Healthy Volunteers</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-announces-successful-delivery-of-cbd-and-thc-through-the-skin-of-healthy-volunteers</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-announces-successful-delivery-of-cbd-and-thc-through-the-skin-of-healthy-volunteers</guid>
      <pubDate>Mon, 14 Nov 2022 12:32:19 GMT</pubDate>
      <description>Wellbeing Subsidiary KGK Science Announces Successful Delivery of CBD and THC Through the Skin of Healthy Volunteers.</description>
    </item>
    <item>
      <title>Wellbeing Digital Subsidiary KGK to Participate in Microdose Wonderland Miami Conference</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-subsidiary-kgk-to-participate-in-microdose-wonderland-miami-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-subsidiary-kgk-to-participate-in-microdose-wonderland-miami-conference</guid>
      <pubDate>Wed, 02 Nov 2022 11:33:11 GMT</pubDate>
      <description>Wellbeing Digital Subsidiary KGK to Participate in Microdose Wonderland Miami Conference.</description>
    </item>
    <item>
      <title>Wellbeing Announces Definitive Agreement to Divest IRP Health</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-announces-definitive-agreement-to-divest-irp-health</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-announces-definitive-agreement-to-divest-irp-health</guid>
      <pubDate>Thu, 27 Oct 2022 11:31:53 GMT</pubDate>
      <description>Wellbeing Announces Definitive Agreement to Divest IRP Health.</description>
    </item>
    <item>
      <title>Wellbeing Digital to Participate at this Years’ Wonderland Miami Conference</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-to-participate-at-this-years-wonderland-miami-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-to-participate-at-this-years-wonderland-miami-conference</guid>
      <pubDate>Tue, 25 Oct 2022 11:31:13 GMT</pubDate>
      <description>Wellbeing Digital to Participate at this Years’ Wonderland Miami Conference.</description>
    </item>
    <item>
      <title>Wellbeing Digital Subsidiary KGK to Participate in the Supply Side West Conference</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-subsidiary-kgk-to-participate-in-the-supply-side-west-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-subsidiary-kgk-to-participate-in-the-supply-side-west-conference</guid>
      <pubDate>Thu, 13 Oct 2022 11:31:44 GMT</pubDate>
      <description>Wellbeing Digital Subsidiary KGK to Participate in the Supply Side West Conference.</description>
    </item>
    <item>
      <title>Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta’s Move to Regulate the Use of Psychedelics</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-and-subsidiary-kgk-science-applauds-the-government-of-albertas-move-to-regulate-the-use-of-psychedelics</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-and-subsidiary-kgk-science-applauds-the-government-of-albertas-move-to-regulate-the-use-of-psychedelics</guid>
      <pubDate>Tue, 11 Oct 2022 11:33:10 GMT</pubDate>
      <description>Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta’s Move to Regulate the Use of Psychedelics.</description>
    </item>
    <item>
      <title>Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-announces-psilocybin-microdose-capsule-formulation-to-be-submitted-to-health-canada-for-phase-2a-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-subsidiary-kgk-science-announces-psilocybin-microdose-capsule-formulation-to-be-submitted-to-health-canada-for-phase-2a-trial</guid>
      <pubDate>Thu, 06 Oct 2022 11:55:57 GMT</pubDate>
      <description>Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial.</description>
    </item>
    <item>
      <title>Wellbeing Digital Signs LOI Manage Additional Clinics</title>
      <link>https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-signs-loi-manage-additional-clinics</link>
      <guid isPermaLink="true">https://6ix.com/company/ketamineone-capital-limited/news/wellbeing-digital-signs-loi-manage-additional-clinics</guid>
      <pubDate>Tue, 04 Oct 2022 11:32:17 GMT</pubDate>
      <description>Wellbeing Digital Signs LOI Manage Additional Clinics.</description>
    </item>
  </channel>
</rss>